Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

Company Overview - Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing oral antiviral therapies for serious viral diseases [3] - The company has developed a proprietary nucleos(t)ide prodrug platform aimed at treating single-stranded ribonucleic acid (ssRNA) viruses, which are a significant cause of serious viral infections [3] - Atea's lead program is in global Phase 3 development, focusing on a combination regimen of bemnifosbuvir, a nucleotide analog polymerase inhibitor, and ruzasvir, an NS5A inhibitor, specifically targeting Hepatitis C Virus (HCV) [3] Upcoming Events - Members of Atea's management team will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 1:05 p.m. ET in New York [1] - A live webcast of the presentation will be available on the company's website, with an archived version accessible for at least 90 days following the event [2]